+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), End Use (Pharma & CRO Industry, Hospitals), Region, with Growth Forecasts, 2025-2030- Product Image
Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), End Use (Pharma & CRO Industry, Hospitals), Region, with Growth Forecasts, 2025-2030- Product Image
New

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), End Use (Pharma & CRO Industry, Hospitals), Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 4375434
Description Jump to:
The Non-alcoholic Steatohepatitis Biomarkers Market was valued at USD 1.59 Billion in 2024, and is projected to reach USD 5.68 Billion by 2030, rising at a CAGR of 23.30%. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights

  • On the basis of type, the serum biomarkers segment led the market with the largest revenue share of 31.2% in 2024, attributed to their ability to provide non-invasive, cost-effective, reliable diagnostic options.
  • The hepatic fibrosis biomarkers segment is projected to grow at the fastest CAGR during the forecast period, fueled by their crucial role in assessing the severity and progression of liver damage.
  • On the basis of end use, the pharma & CRO industry segment dominated the market with the largest share in 2024, driven by its critical role in drug development, clinical trials, and biomarker validation.
  • The diagnostic labs segment is set to be the fastest-growing segment from 2025 to 2030 due to increasing awareness and the rising demand for early detection and diagnosis.
  • North America accounted for the largest share of almost 54% in 2024, owing toits advanced healthcare infrastructure, high awareness of liver diseases, and substantial research investments.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. End Use
1.2.3. Regional Scope
1.2.4. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. End Use Outlook
2.2.3. Regional Outlook
2.3. Competitive Scenario
Chapter 3. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
4.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Serum Biomarkers
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Hepatic Fibrosis Biomarkers
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Apoptosis Biomarkers
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Oxidative Stress Biomarkers
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Estimates & Trend Analysis
5.1. End Use Segment Dashboard
5.2. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
5.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Pharma & CRO Industry
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Hospitals
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Diagnostic Labs
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Academic Research Institutes
5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Non-alcoholic Steatohepatitis Biomarkers Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Regulatory Framework/ Reimbursement Structure
6.4.1.3. Competitive Scenario
6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework/ Reimbursement Structure
6.4.2.3. Competitive Scenario
6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.3. Mexico
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework/ Reimbursement Structure
6.4.3.3. Competitive Scenario
6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. U.K.
6.5.1.1. Key Country Dynamics
6.5.1.2. Regulatory Framework/ Reimbursement Structure
6.5.1.3. Competitive Scenario
6.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework/ Reimbursement Structure
6.5.2.3. Competitive Scenario
6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.3. France
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework/ Reimbursement Structure
6.5.3.3. Competitive Scenario
6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.4. Italy
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework/ Reimbursement Structure
6.5.4.3. Competitive Scenario
6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework/ Reimbursement Structure
6.5.5.3. Competitive Scenario
6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework/ Reimbursement Structure
6.5.6.3. Competitive Scenario
6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework/ Reimbursement Structure
6.5.7.3. Competitive Scenario
6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework/ Reimbursement Structure
6.5.8.3. Competitive Scenario
6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Regulatory Framework/ Reimbursement Structure
6.6.1.3. Competitive Scenario
6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework/ Reimbursement Structure
6.6.2.3. Competitive Scenario
6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework/ Reimbursement Structure
6.6.3.3. Competitive Scenario
6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework/ Reimbursement Structure
6.6.4.3. Competitive Scenario
6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework/ Reimbursement Structure
6.6.5.3. Competitive Scenario
6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.6. Thailand
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework/ Reimbursement Structure
6.6.6.3. Competitive Scenario
6.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework/ Reimbursement Structure
6.7.2.3. Competitive Scenario
6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework/ Reimbursement Structure
6.7.3.3. Competitive Scenario
6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework/ Reimbursement Structure
6.8.2.3. Competitive Scenario
6.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework/ Reimbursement Structure
6.8.3.3. Competitive Scenario
6.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework/ Reimbursement Structure
6.8.4.3. Competitive Scenario
6.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework/ Reimbursement Structure
6.8.5.3. Competitive Scenario
6.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, by Key Market Participants
7.2. Company/ Competition Categorization
7.3. Vendor Landscape
7.3.1. Key Company Heat Map Analysis, 2024
7.4. Company Profiles
7.4.1. GENFIT
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Prometheus Laboratories
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Siemens Healthineers AG
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. BioPredictive
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Quest Diagnostics
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. AstraZeneca
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Exalenz Bioscience Ltd (meridian bioscience)
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Labcorp
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Pfizer Inc.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Bristol-Myers Squibb Company
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Region, 2018-2030 (USD Million)
Table 4 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 5 Global Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 6 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018-2030 (USD Million)
Table 7 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 8 North America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 9 U.S. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 10 U.S Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 11 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 12 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 13 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 14 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 15 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018-2030 (USD Million)
Table 16 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 17 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 18 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 19 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 20 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 21 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 22 France Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 23 France Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 24 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 25 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 26 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 27 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 28 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 29 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 30 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 31 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 32 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 33 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 34 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018-2030 (USD Million)
Table 35 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 36 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 37 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 38 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 39 China Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 40 China Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 41 India Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 42 India Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 43 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 44 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 45 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 46 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 47 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 48 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 49 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018-2030 (USD Million)
Table 50 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 51 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 52 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 53 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 54 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 55 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 56 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018-2030 (USD Million)
Table 57 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 58 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 59 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 60 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 61 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 62 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 63 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 64 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
Table 65 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018-2030 (USD Million)
Table 66 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market Research Process
Figure 2 Data Triangulation Techniques
Figure 3 Primary Research Pattern
Figure 4 Primary Interviews
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 QFD Modeling for Market Share Assessment
Figure 8 Market Formulation & Validation
Figure 9 Non-alcoholic Steatohepatitis Biomarkers Market: Market Outlook
Figure 10 Non-alcoholic Steatohepatitis Biomarkers Competitive Insights
Figure 11 Parent Market Outlook
Figure 12 Related/Ancillary Market Outlook
Figure 13 Penetration and Growth Prospect Mapping
Figure 14 Industry Value Chain Analysis
Figure 15 Non-alcoholic Steatohepatitis Biomarkers Market Driver Impact
Figure 16 Non-alcoholic Steatohepatitis Biomarkers Market Restraint Impact
Figure 17 Non-alcoholic Steatohepatitis Biomarkers Market Strategic Initiatives Analysis
Figure 18 Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
Figure 19 Non-alcoholic Steatohepatitis Biomarkers Market: Type Outlook and Key Takeaways
Figure 20 Serum Biomarkers Market Estimates and Forecast, 2018-2030
Figure 21 Hepatic Fibrosis Biomarkers Market Estimates and Forecast, 2018-2030
Figure 22 Apoptosis Biomarkers Market Estimates and Forecast, 2018-2030
Figure 23 Oxidative Stress Biomarkers Market Estimates and Forecast, 2018-2030
Figure 24 Others Market Estimates and Forecast, 2018-2030
Figure 25 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
Figure 26 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Outlook and Key Takeaways
Figure 27 Pharma & CRO Industry Market, 2018-2030 (USD Million)
Figure 28 Hospitals Market, 2018-2030 (USD Million)
Figure 29 Diagnostic Labs Market, 2018-2030 (USD Million)
Figure 30 Academic Research Institutes Market, 2018-2030 (USD Million)
Figure 31 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Movement Analysis
Figure 32 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Outlook and Key Takeaways
Figure 33 North America Market Estimates and Forecasts, 2018-2030
Figure 34 U. S. Market Estimates and Forecasts, 2018-2030
Figure 35 Canada Market Estimates and Forecasts, 2018-2030
Figure 36 Mexico Market Estimates and Forecasts, 2018-2030
Figure 37 Europe Market Estimates and Forecasts, 2018-2030
Figure 38 U. K. Market Estimates and Forecasts, 2018-2030
Figure 39 Germany Market Estimates and Forecasts, 2018-2030
Figure 40 France Market Estimates and Forecasts, 2018-2030
Figure 41 Italy Market Estimates and Forecasts, 2018-2030
Figure 42 Spain Market Estimates and Forecasts, 2018-2030
Figure 43 Denmark Market Estimates and Forecasts, 2018-2030
Figure 44 Sweden Market Estimates and Forecasts, 2018-2030
Figure 45 Norway Market Estimates and Forecasts, 2018-2030
Figure 46 Asia Pacific Market Estimates and Forecasts, 2018-2030
Figure 47 Japan Market Estimates and Forecasts, 2018-2030
Figure 48 China Market Estimates and Forecasts, 2018-2030
Figure 49 India Market Estimates and Forecasts, 2018-2030
Figure 50 South Korea Market Estimates and Forecasts, 2018-2030
Figure 51 Australia Market Estimates and Forecasts, 2018-2030
Figure 52 Thailand Market Estimates and Forecasts, 2018-2030
Figure 53 Latin America Market Estimates and Forecasts, 2018-2030
Figure 54 Brazil Market Estimates and Forecasts, 2018-2030
Figure 55 Argentina Market Estimates and Forecasts, 2018-2030
Figure 56 Middle East & Africa Market Estimates and Forecasts, 2018-2030
Figure 57 South Africa Market Estimates and Forecasts, 2018-2030
Figure 58 Saudi Arabia Market Estimates and Forecasts, 2018-2030
Figure 59 UAE Market Estimates and Forecasts, 2018-2030
Figure 60 Kuwait Market Estimates and Forecasts, 2018-2030

Companies Mentioned

The companies profiled in this Non-alcoholic Steatohepatitis Biomarkers market report include:
  • GENFIT
  • Prometheus Laboratories
  • Siemens Healthineers AG
  • BioPredictive
  • Quest Diagnostics
  • AstraZeneca
  • Exalenz Bioscience Ltd (meridian bioscience)
  • Labcorp
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.68 Billion
Compound Annual Growth Rate23.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Non-Alcoholic Steatohepatitis Biomarkers Market Report 2025 - Product Image

Non-Alcoholic Steatohepatitis Biomarkers Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030 - Product Image

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis), End-use (Hospitals, Diagnostic Labs), and Segment Forecasts, 2024-2030 - Product Image

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis), End-use (Hospitals, Diagnostic Labs), and Segment Forecasts, 2024-2030

  • Report
  • 70 Pages
  • United States
From
Brain Biomarkers Market by Product, Biomarker Type, Technology, Indication, End User - Global Forecast to 2030 - Product Image

Brain Biomarkers Market by Product, Biomarker Type, Technology, Indication, End User - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Rare Biomarkers Specimen Collection & Stabilization Market by Specimen Type, End User, Application, Stabilization Technique, Collection Method - Global Forecast to 2030 - Product Image

Rare Biomarkers Specimen Collection & Stabilization Market by Specimen Type, End User, Application, Stabilization Technique, Collection Method - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From

About the NASH Biomarker Market

NASH biomarkers are a type of biomarker used to diagnose and monitor non-alcoholic steatohepatitis (NASH). NASH is a chronic liver disease that is characterized by the accumulation of fat in the liver, inflammation, and fibrosis. Biomarkers are biological molecules that can be used to measure the presence or absence of a disease, or to monitor the progression of a disease. NASH biomarkers are used to diagnose NASH, to monitor the progression of the disease, and to assess the effectiveness of treatments. NASH biomarkers are typically measured in the blood or urine, and can include markers of liver injury, inflammation, fibrosis, and metabolic dysregulation. Examples of NASH biomarkers include alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and C-reactive protein (CRP). The NASH biomarker market is a rapidly growing market, driven by the increasing prevalence of NASH and the need for more accurate and reliable diagnostic and monitoring tools. Companies in the NASH biomarker market include Bio-Rad Laboratories, Siemens Healthineers, Abbott Laboratories, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.